Sevelamer hydrochloride is an orally active and phosphate binding agent used for research of hyperphosphatemia with chronic kidney disease. Sevelamer hydrochloride consists of polyallylamine that is crosslinked with epichlorohydrin^[1][2][3].

Sevelamer hydrochloride (15 mg/mL; pH=6 or 8) decreases serum levels of gut-derived uremic toxins (such as IAA) or limits the elevation of gut-derived uremic toxins (initial concentration=1 μg/mL or 10 μg/mL)^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Sevelamer hydrochloride (1% mixed in diet; p.o.; once daily for 5 weeks) reduces Npt2b-deficient mice serum phosphate levels, but fails to reduce the level in uremic WT mice^[3].
Sevelamer hydrochloride leads to a significant decrease in osteoclast number in uremic WT mice with a trend toward further decrease in Npt2b^-/- mice^[3].
Sevelamer hydrochloride leads to a significant increase in Npt2b protein expression^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

186.08 (monomer)

(C₃H₇N.C₃H₅ClO)x.xHCl

152751-57-0

固體

White to off-white

鹽酸司維拉姆

Room temperature in continental US; may vary elsewhere.

• [1]. Sevelamer, From Wikipedia

  [2]. Bennis Y, et al. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Toxins (Basel). 2019 May 17;11(5):279.  [Content Brief]

  [3]. Susan C Schiavi, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012 Oct;23(10):1691-700.  [Content Brief]